PRIA, Government Policy, Made Personal

Summary

The CDC director can run and grow proven programs to prevent overdoses. The CDC can train and help States, local governments, and Indian tribes, and give them grants. Work can include improving prescription drug monitoring programs so they are easier to use, more real-time, can alert providers to possible misuse, share de-identified reports with the right agencies, connect with health records, exchange data across States, and give doctors tools to review prescribing. The CDC can also fund community and health system prevention projects, test what works, try new prevention ideas like public education, and support projects that detect and quickly respond to misuse and changing drug patterns (including things like wastewater surveillance when it helps and follows privacy rules). The CDC can collect better overdose data, train partners, and give grants for that work. That means faster public reporting of fatal and nonfatal overdoses; using toxicology, autopsy, emergency department, and death-scene information; moving to electronic death records; finding risk factors; and helping coroners, medical examiners, and labs improve testing and reporting. The CDC may give priority to places with especially high overdose rates. Controlled substance: the federal term for regulated drugs. Indian tribe: the federal term for a tribe. Congress authorized $505,579,000 for each fiscal year 2026 through 2030 for these activities.

Title 42, §280b–1

The Public Health and Welfare, Source: USLM XML via OLRC

(a)(1)The Director of the Centers for Disease Control and Prevention may—

(A)to the extent practicable, carry out and expand any evidence-based prevention activities described in paragraph (2);

(B)provide training and technical assistance to States, localities, and Indian Tribes for purposes of carrying out such activity; and

(C)award grants to States, localities, and Indian Tribes for purposes of carrying out such activity.

(2)An evidence-based prevention activity described in this paragraph is any of the following activities:

(A)Improving the efficiency and use of a new or currently operating prescription drug monitoring program, including by—

(i)encouraging all authorized users (as specified by the State or other entity) to register with and use the program;

(ii)enabling such users to access any updates to information collected by the program in as close to real-time as possible;

(iii)improving the ease of use of such program;

(iv)providing for a mechanism for the program to notify authorized users of any potential misuse or abuse of controlled substances and any detection of inappropriate prescribing or dispensing practices relating to such substances;

(v)encouraging the analysis of prescription drug monitoring data for purposes of providing de-identified, aggregate reports based on such analysis to State public health agencies, State substance abuse agencies, State licensing boards, and other appropriate State agencies, as permitted under applicable Federal and State law and the policies of the prescription drug monitoring program and not containing any protected health information, to prevent inappropriate prescribing, drug diversion, or abuse and misuse of controlled substances, and to facilitate better coordination among agencies;

(vi)enhancing interoperability between the program and any health information technology (including certified health information technology), including by integrating program data into such technology;

(vii)updating program capabilities to respond to technological innovation for purposes of appropriately addressing the occurrence and evolution of controlled substance overdoses;

(viii)facilitating and encouraging data exchange between the program and the prescription drug monitoring programs of other States;

(ix)enhancing data collection and quality, including improving patient matching and proactively monitoring data quality;

(x)providing prescriber and dispenser practice tools, including prescriber practice insight reports for practitioners to review their prescribing patterns in comparison to such patterns of other practitioners in the specialty; and

(xi)meeting the purpose of the program established under section 280g–3 of this title, as described in section 280g–3(a) of this title.

(B)Promoting community or health system interventions.

(C)Evaluating interventions to prevent controlled substance overdoses and associated risks.

(D)Implementing projects to advance an innovative prevention approach with respect to new and emerging public health crises and opportunities to address such crises, such as enhancing public education and awareness on the risks associated with substances causing overdose.

(3)The Director may award grants to States, localities, and Indian Tribes for the following purposes:

(A)To carry out innovative projects for grantees to detect, identify, and rapidly respond to controlled substance misuse, abuse, and overdoses, and associated risk factors, including changes in patterns of such controlled substance use. Such projects may include the use of innovative, evidence-based strategies for detecting such patterns, such as wastewater surveillance, if proven to support actionable prevention strategies, in a manner consistent with applicable Federal and State privacy laws.

(B)For any other evidence-based activity for preventing controlled substance misuse, abuse, and overdoses as the Director determines appropriate.

(4)The Director, in coordination with the Assistant Secretary for Mental Health and Substance Use and the National Mental Health and Substance Use Policy Laboratory established under section 290aa–0 of this title, as appropriate and applicable, may conduct studies and evaluations to address substance use disorders, including preventing substance use disorders or other related topics the Director determines appropriate.

(b)(1)The Director of the Centers for Disease Control and Prevention may—

(A)to the extent practicable, carry out any controlled substance overdose data collection activities described in paragraph (2);

(B)provide training and technical assistance to States, localities, and Indian Tribes for purposes of carrying out such activity;

(C)award grants to States, localities, and Indian Tribes for purposes of carrying out such activity; and

(D)coordinate with the Assistant Secretary for Mental Health and Substance Use to collect data pursuant to section 290aa–4(d)(1)(A) of this title (relating to the number of individuals admitted to emergency departments as a result of the abuse of alcohol or other drugs).

(2)A controlled substance overdose data collection, analysis, and dissemination activity described in this paragraph is any of the following activities:

(A)Improving the timeliness of reporting data to the public, including data on fatal and nonfatal overdoses of controlled substances.

(B)Enhancing the comprehensiveness of controlled substance overdose data by collecting information on such overdoses, and associated risk factors, from appropriate sources such as toxicology reports, autopsy reports, death scene investigations, and emergency departments.

(C)Modernizing the system for monitoring and identifying causes of death related to controlled substance overdoses to use an electronic-based system.

(D)Using data to help identify risk factors associated with controlled substance overdoses.

(E)Supporting entities involved in providing information on controlled substance overdoses, such as coroners, medical examiners, and public health laboratories, to improve accurate testing and standardized reporting of causes and contributing factors to controlled substances overdoses and analysis of various opioid analogues and other emerging substances related to controlled substance overdoses.

(F)Working to enable and encourage the access, exchange, and use of information regarding controlled substance overdoses and associated risk factors among data sources and entities.

(c)In awarding grants to States under subsections (a) and (b), the Director of the Centers for Disease Control and Prevention may give priority to jurisdictions with a disproportionately high rate of drug overdoses or drug overdose deaths, as applicable.

(d)In this section:

(1)The term “controlled substance” has the meaning given that term in section 802 of title 21.

(2)The term “Indian tribe” has the meaning given that term in section 5304 of title 25.

(e)For purposes of carrying out this section, section 280g–3 of this title, and section 290bb–25g of this title, there is authorized to be appropriated $505,579,000 for each of fiscal years 2026 through 2030.

Notes & Related Subsidiaries

Editorial Notes

Prior Provisions

A prior section 280b–1, act

July 1, 1944, ch. 373, title III, § 392, as added Pub. L. 99–649, § 3, Nov. 10, 1986, 100 Stat. 3634; amended Pub. L. 101–558, § 2(b), Nov. 15, 1990, 104 Stat. 2772; Pub. L. 102–531, title III, §§ 301, 312(d)(4), Oct. 27, 1992, 106 Stat. 3482, 3504; Pub. L. 103–183, title II, § 203(a)(2), (b)(1), Dec. 14, 1993, 107 Stat. 2232, which related to prevention and control activities, was transferred to section 280b–0 of this title. Another prior section 280b–1, act

July 1, 1944, ch. 373, title III, § 391, as added Oct. 22, 1965, Pub. L. 89–291, § 2, 79 Stat. 1059; amended Mar. 13, 1970, Pub. L. 91–212, § 10(b)(3), 84 Stat. 66;

July 23, 1974, Pub. L. 93–353, title II, § 202(b), 88 Stat. 372, defined “sciences related to health”, “National Medical Libraries Assistance Advisory Board”, “Board”, and “medical library”, prior to repeal by Pub. L. 99–158, § 3(b), Nov. 20, 1985, 99 Stat. 879.

Amendments

2025—Subsec. (a)(2)(C). Pub. L. 119–44, § 103(a)(1)(A), inserted “and associated risks” before period at end. Subsec. (a)(2)(D). Pub. L. 119–44, § 103(a)(1)(B), substituted “substances causing overdose” for “opioids”. Subsec. (a)(3). Pub. L. 119–44, § 103(b)(1), substituted “and Indian Tribes for the following purposes:” for “and Indian Tribes—” in introductory provisions. Subsec. (a)(3)(A). Pub. L. 119–44, § 103(b)(2), amended subpar. (A) generally. Prior to amendment, subpar. (A) read as follows: “to carry out innovative projects for grantees to rapidly respond to controlled substance misuse, abuse, and overdoses, including changes in patterns of controlled substance use; and”. Subsec. (a)(3)(B). Pub. L. 119–44, § 103(b)(3), substituted “For any” for “for any”. Subsec. (b)(2)(B). Pub. L. 119–44, § 103(a)(2)(A), inserted “, and associated risk factors,” after “such overdoses”. Subsec. (b)(2)(C). Pub. L. 119–44, § 103(a)(2)(B), substituted “monitoring and identifying” for “coding”. Subsec. (b)(2)(E). Pub. L. 119–44, § 103(a)(2)(C), inserted a comma after “public health laboratories” and “and other emerging substances related” after “analogues”. Subsec. (b)(2)(F). Pub. L. 119–44, § 103(a)(2)(D), inserted “and associated risk factors” after “overdoses”. Subsec. (e). Pub. L. 119–44, § 103(c), substituted “$505,579,000 for each of fiscal years 2026 through 2030” for “$496,000,000 for each of fiscal years 2019 through 2023”. 2022—Subsecs. (a)(1)(B), (C), (b)(1)(B), (C). Pub. L. 117–328, § 1271(b)(2), substituted “Indian Tribes” for “Indian tribes”. Subsecs. (c) to (e). Pub. L. 117–328, § 1271(b)(1), added subsec. (c) and redesignated former subsecs. (c) and (d) as (d) and (e), respectively.

§280b–1 Preventing Overdoses of Controlled Substances